

**Portfolio Building Block World Pharma and Biotech Index ETF**  
**Schedule of Investments**  
**January 31, 2026 (Unaudited)**

<b>COMMON STOCKS - 99.5%</b>	<b>Shares</b>	<b>Value</b>
<b>Consumer Staple Products - 1.0%</b>		
Haleon PLC	72,864	\$ 378,853
<b>Health Care - 98.5%<sup>(a)</sup></b>		
AbbVie, Inc.	10,501	2,341,828
Alnylam Pharmaceuticals, Inc. <sup>(b)</sup>	1,091	368,823
Amgen, Inc.	4,536	1,550,768
Argenx SE <sup>(b)</sup>	541	452,968
Astellas Pharma, Inc.	13,832	192,246
AstraZeneca PLC	8,832	1,648,281
Bayer AG	8,142	431,616
Biogen, Inc. <sup>(b)</sup>	1,241	223,243
BioMarin Pharmaceutical, Inc. <sup>(b)</sup>	1,518	85,828
Bridgebio Pharma, Inc. <sup>(b)</sup>	1,379	106,555
Bristol-Myers Squibb Co.	16,976	934,529
Chugai Pharmaceutical Co. Ltd.	4,277	244,016
CSL Ltd.	4,004	508,883
Daiichi Sankyo Co. Ltd.	13,800	253,707
Elanco Animal Health, Inc. <sup>(b)</sup>	4,139	99,667
Eli Lilly & Co.	5,094	5,283,242
Exact Sciences Corp. <sup>(b)</sup>	1,518	155,352
Exelixis, Inc. <sup>(b)</sup>	2,072	85,698
Galderma Group AG	1,104	206,306
Genmab A/S <sup>(b)</sup>	535	172,333
Gilead Sciences, Inc.	10,351	1,469,324
GSK PLC	32,982	849,296
Incyte Corp. <sup>(b)</sup>	1,656	165,716
Insmmed, Inc. <sup>(b)</sup>	1,794	281,425
Ionis Pharmaceuticals, Inc. <sup>(b)</sup>	1,379	114,002
Johnson & Johnson	14,354	3,261,946
Madrigal Pharmaceuticals, Inc. <sup>(b)</sup>	148	72,418
Merck & Co., Inc.	15,319	1,689,226
Merck KGaA	1,103	164,745
Natera, Inc. <sup>(b)</sup>	1,104	255,179
Neurocrine Biosciences, Inc. <sup>(b)</sup>	827	112,522
Novartis AG	12,007	1,787,212
Novo Nordisk A/S - Class B	26,635	1,568,050
Otsuka Holdings Co, Ltd.	2,887	172,947
Pfizer, Inc.	47,196	1,247,862
Regeneron Pharmaceuticals, Inc.	833	617,628
Revolution Medicines, Inc. <sup>(b)</sup>	1,380	133,791
Roche Holding AG - Class BR	148	68,421
Roche Holding AG, Genusschein Shares	4,154	1,891,835

Royalty Pharma PLC - Class A	2,898	\$	120,789
Sandoz Group AG	3,450		274,100
Sanofi SA	9,522		897,169
Shionogi & Co., Ltd.	4,422		90,986
Takeda Pharmaceutical Co. Ltd.	13,580		461,470
Teva Pharmaceutical Industries Ltd. <sup>(b)</sup>	9,391		306,915
UCB SA	975		296,242
United Therapeutics Corp. <sup>(b)</sup>	395		185,449
Vertex Pharmaceuticals, Inc. <sup>(b)</sup>	2,082		978,332
Viatis, Inc.	9,522		124,643
Zoetis, Inc. - Class A	3,726		465,079
			<u>35,470,608</u>

**TOTAL COMMON STOCKS (Cost \$35,721,321)**

35,849,461

---

**SHORT-TERM INVESTMENTS - 0.4%**

<b>Money Market Funds - 0.4%</b>	<b>Shares</b>	<b>Value</b>
Dreyfus Treasury Securities Cash Management, 3.57% <sup>(c)</sup>	149,553	<u>149,553</u>
<b>TOTAL SHORT-TERM INVESTMENTS (Cost \$149,553)</b>		<u>149,553</u>
<b>TOTAL INVESTMENTS - 99.9% (Cost \$35,870,874)</b>		\$ 35,999,014
Other Assets in Excess of Liabilities - 0.1%		<u>27,299</u>
<b>TOTAL NET ASSETS - 100.0%</b>		<u>\$ 36,026,313</u>

Percentages are stated as a percent of net assets.

PLC            Public Limited Company

- (a) To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors.
- (b) Non-income producing security.
- (c) The rate shown represents the 7-day annualized effective yield as of January 31, 2026.